Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment...
25 KB (1,922 words) - 02:45, 30 April 2024
program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results...
13 KB (969 words) - 19:29, 20 December 2023
treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab. "Tremfya...
14 KB (1,017 words) - 04:34, 12 May 2024
Management of Crohn's disease (section Ustekinumab)
needed] Ustekinumab (CNTO 1275) is a monoclonal antibody that suppresses cytokines IL-12 and IL-23. Originally designed to treat psoriasis, ustekinumab was...
44 KB (4,607 words) - 00:50, 4 May 2024
bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS". Therapeutic Goods...
11 KB (668 words) - 07:03, 1 April 2024
such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development of biological therapy as a modality to treat...
28 KB (3,343 words) - 13:52, 22 March 2024
received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023. Products under development include biosimilars of...
11 KB (914 words) - 22:12, 28 November 2023
share a common domain, p40, which is the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have...
115 KB (12,972 words) - 04:30, 13 May 2024
Armando; Moreira, Ana Isabel (2016-05-24). "Inverse psoriasis treated with ustekinumab". BMJ Case Reports. BMJ: bcr2016215019. doi:10.1136/bcr-2016-215019....
7 KB (611 words) - 16:36, 7 April 2024
is one of the therapeutic targets to treat the inflammatory diseases. Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat...
20 KB (2,192 words) - 23:02, 27 November 2023
showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo. However, in May 2015, Amgen announced that it was ending...
9 KB (628 words) - 03:23, 20 April 2024
certolizumab pegol and adalimumab, as well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab...
32 KB (3,436 words) - 16:36, 22 April 2024
Japan for use in treating psoriatic arthritis. The anti-IL-23 antibody ustekinumab can also be used to effectively treat psoriasis by indirectly reducing...
35 KB (3,989 words) - 18:59, 2 April 2024
disease ulcerative colitis ankylosing spondylitis inhibits TNF-α human ustekinumab Crohn's disease ulcerative colitis plaque psoriasis psoriatic arthritis...
47 KB (4,798 words) - 06:45, 26 May 2024
antibodies, such as infliximab, adalimumab, certolizumab, vedolizumab, ustekinumab, natalizumab,risankizumab-rzaa, and upadacitinib Hydrocortisone should...
160 KB (18,309 words) - 21:07, 4 June 2024
and Th17 T-cells. IL-12 and IL-23 signaling is blocked by the biologic ustekinumab and IL-23 is blocked by guselkumab, mirikizumab and risankizumab, medications...
141 KB (16,072 words) - 23:23, 16 May 2024
history, preferences, and the recommendations of the healthcare provider. Ustekinumab has frequently been used as a second-line therapy for AS, but it has...
56 KB (5,960 words) - 20:25, 28 May 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (1,841 words) - 22:50, 30 April 2024
tocilizumab-bavi/Tofidence tocilizumab/Actemra October 2023 ustekinumab-auub/Wezlana ustekinumab/Stelara December 2023 bevacizumab-tnjn/Avzivi bevacizumab/Avastin...
95 KB (6,480 words) - 22:51, 13 May 2024
Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12 and IL-23 Lebrikizumab Ustekinumab IL-17A...
7 KB (299 words) - 13:45, 27 April 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
15 KB (1,152 words) - 13:11, 2 June 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
14 KB (1,578 words) - 14:00, 26 February 2024
1 9.9 3 etanercept rheumatoid arthritis Enbrel 7.2 7.6 7.9 8.0 8.1 4 ustekinumab psoriasis Stelara 2.0 2.6 3.7 5.0 6.6 5 pembrolizumab oncology Keytruda...
29 KB (281 words) - 04:19, 27 November 2023
Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab...
3 KB (367 words) - 15:37, 25 January 2024
for ANTM on Oxygen. She appears in the 2012 commercial for Stelara (Ustekinumab), a plaque psoriasis treatment. English has taken part in the Seventh...
25 KB (2,118 words) - 16:21, 1 February 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
24 KB (2,070 words) - 07:13, 15 March 2024
results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis. 2014: In November, construction...
97 KB (7,882 words) - 18:47, 29 May 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
16 KB (1,451 words) - 21:00, 23 April 2024
etanercept and adalimumab as well as the anti-IL12/23 biological treatment ustekinumab. In cases where more conventional systemic treatments such as psoralen...
33 KB (3,686 words) - 07:30, 20 May 2024
originate from a human. An example of a human monoclonal antibody is ustekinumab, which treats psoriasis. During the early stages of the COVID-19 pandemic...
20 KB (2,374 words) - 10:03, 20 December 2023